300142 沃森生物
按盤價 
14.510 +0.300 (+2.111%)
14.510 +0.300 (+2.111%) | 2024/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 2,141,346 | -32.19% | 4,113,772 | 5,086,445 | 3,462,831 | 2,939,021 | |
| 減：營業總成本 | 1,756,031 | -24.34% | 3,152,213 | 3,806,223 | 2,627,638 | 1,912,676 | |
| 其中:營業成本 | 440,624 | -2.36% | 597,556 | 609,469 | 394,339 | 399,810 | |
| 財務費用 | (30,050) | -43.50% | (70,993) | (62,981) | (38,721) | (30,698) | |
| 資產減值損失 | (98,211) | 681.19% | (162,640) | (61,466) | (11,845) | (4,919) | |
| 公允價值變動收益 | (93,690) | 39.03% | (234,750) | (199,335) | (280,737) | 279,890 | |
| 投資收益 | 4,897 | -22.20% | 7,114 | 11,797 | 57,876 | 5,400 | |
| 其中：對聯營企業和合營企業的投資收益 | 75 | -117.09% | 382 | (1,074) | (932) | 181 | |
| 營業利潤 | 286,083 | -63.29% | 613,966 | 1,099,440 | 710,275 | 1,376,282 | |
| 利潤總額 | 373,789 | -51.72% | 598,976 | 1,070,465 | 708,945 | 1,373,304 | |
| 減：所得稅費用 | 23,148 | -69.93% | 87,651 | 132,239 | 107,593 | 162,117 | |
| 淨利潤 | 350,641 | -49.71% | 511,325 | 938,226 | 601,352 | 1,211,187 | |
| 減：非控股權益 | 94,282 | -34.46% | 91,935 | 209,574 | 173,604 | 208,000 | |
| 股東淨利潤 | 256,359 | -53.67% | 419,390 | 728,652 | 427,748 | 1,003,187 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.160 | -53.64% | 0.262 | 0.455 | 0.273 | 0.652 | |
| 每股派息 (元) * | -- | -- | 0.010 | 0.010 | 0.027 | 0.070 | |
| 每股淨資產 (元) * | 5.996 | 0.90% | 5.817 | 5.652 | 5.298 | 4.233 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 04/11/2024 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
